Clinical Trials · NCT01511393
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
- Phase
- N/A
- Recruitment status
- Enrolling By Invitation
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 6,750
- Start date
- Jan 2012
- Locations
- 1 site, United States
- Primary endpoint
- Annual incidence of MTC in the US to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market.